Frazier Healthcare Appoints David Socks as Venture Partner, Establishes Boston Presence

MENLO PARK, Calif.--Frazier Healthcare, a leading provider of venture and growth buyout capital to emerging healthcare companies, announced today that David Socks has joined the Frazier Life Sciences team as a Venture Partner based in the Boston area to lead the firm's life sciences company creation efforts.

Prior to joining Frazier, Mr. Socks co-founded Incline Therapeutics in 2010 and served as its President and Chief Operating Officer until its sale to The Medicines Company (NASDAQ: MDCO) in 2013 for up to $390M. He previously co-founded Cadence Pharmaceuticals in 2004 and served as its Senior Vice President, Corporate Development and Strategy. Cadence completed its IPO in 2006 (NASDAQ: CADX), received FDA approval for OFIRMEV (acetaminophen injection) in 2010, and was sold to Mallinckrodt (NYSE: MKN) in 2013 for $1.3 billion. Both Incline and Cadence were previous portfolio companies of Frazier Healthcare. Previously, Mr. Socks was a Venture Partner at Windamere Venture Partners where he co-founded more than a half dozen life sciences companies.

"I am very pleased to join the Frazier Life Sciences team with whom I have had a terrific working relationship over the past 12 years across several companies," commented Mr. Socks. "I believe there are tremendous opportunities to form new ventures around development-stage assets with significant potential for advancing human health. I look forward to working with the Frazier Life Sciences team in this endeavor to create great companies and bring important new medicines to patients."

"We enthusiastically welcome David to our Life Sciences team," added Jamie Topper, General Partner. "He is an experienced, talented, and passionate entrepreneur and executive whose arrival reinforces Frazier's long-standing commitment to life sciences company creation. David also provides us with a valuable presence in the highly innovative, fast-growing Boston life sciences community."

About Frazier Healthcare

Founded in 1991, Frazier Healthcare is a leading provider of venture and growth buyout capital to emerging healthcare services and biopharmaceutical companies. With over $2 billion under management across seven funds, Frazier Healthcare has invested in more than 150 companies across the entire development spectrum. Its most recent fund, Frazier Healthcare VII, was closed in 2013 with commitments of $377 million. From venture investments to leveraged recapitalizations, Frazier Healthcare has established itself among entrepreneurs and seasoned executives as a preferred partner to help create and grow successful healthcare companies. The Life Sciences team at Frazier Healthcare focuses on investments in biopharmaceuticals and related areas that are addressing areas of unmet medical need through innovation.

For more information about Frazier Healthcare, visit the company's website at


Frazier Healthcare
Bridget Rauvola, 206-254-1116
Cell: 303-775-2929
[email protected]
Marketing & Investor Relations Partner


Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Polyphor is developing an inhaled version of murepavadin, which targets Pseudomonas aeruginosa infections, but is currently given intravenously.

Japanese pharma Astellas is looking to offload a series of unwanted research projects ahead of Thanksgiving; if you want one, it’s made it very easy.

A re-engineered adenovirus prolonged survival in mouse models of metastatic lung cancer and cleared tumors in about 35% of the animals.